Recombinant modified vaccinia virus Ankara efficiently restimulates human cytotoxic T lymphocytes in vitro

Vaccine

Volumn 19, Issue 2-3, 2000, Pages 327-336

  Dorrell, L ^a   O'Callaghan, C A ^a   Britton, W ^c   Hambleton, S ^a   McMichael, A ^a   Smith, G L ^b   Rowland Jones, S ^a   Blanchard, T J ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c CENTENARY INSTITUTE   (Australia)

Author keywords

Cytotoxic T lymphocyte; MVA strain; Vaccinia virus

Indexed keywords

VIRUS NUCLEOPROTEIN;

ARTICLE; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; IMMUNOGENICITY; IN VITRO STUDY; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TARGET CELL; VACCINIA VIRUS; VIRUS EXPRESSION; VIRUS RECOMBINANT; VIRUS REPLICATION; VIRUS STRAIN;

EID: 0034666722     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(00)00135-3     Document Type: Article

References (31)

1. Moss B., Carroll M.W., Wyatt L.S., Bennink J.R., Hirsch V.M., Goldstein S., et al. Host-range restricted, non-replicating vaccinia virus vectors as vaccine candidates. Adv. Exp. Med. Biol. 397:1996;7-13.
2. Chakrabarti S., Robert-Guroff M., Wong-Staal F. Expression of HTLV-III envelope gene by a recombinant vaccinia virus. Nature. 320:1986;535-537.
3. Cooney E.L., Collier A.C., Greenburg P.D., Coombs R.W., Zarling J., Arditti D.E., et al. Safety and immunological response to recombinant vaccinia virus expressing the HIV envelope gene. Lancet. 337:1991;567-572.
4. Blanchard T., Alcami A., Andrea P., Smith G.L. Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for uses as a human vaccine. J. Gen. Virol. 79:1998;1159-1167.
5. Mayr A., Stickl H., Muller H., Danner K., Singer H. The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behaviour in organisms with a debilitated defence mechanism. Zbl. Bakt. Hyg. I. Abt. Orig. B. 167:1978;375-390.
6. Sutter G.A., Wyatt L.S., Foley P.L., Bennink J.R., Moss B. A recombinant vector derived from the host-range restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus. Vaccine. 12:1994;1032-1040.
7. Schneider J., Gilbert S.C., Blanchard R.J., Hanke T., Robson K.J., Hannan C.M., et al. Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat. Med. 4:1998;397-402.
8. sm env and gag-pol. Charnock R.M., Brown F., Ginsberg H.S., Norrby E. Vaccines 95. 1995;195-200 Cold Spring Harbour Laboratory, Cold Spring Harbour.
9. Hirsch V.M., Fuerst T.R., Sutter G., Carroll M.W., Lang L.C., Goldstein S., et al. Patterns of viral replication correlate with outcome in SIV-infected macaques: effect of prior immunisation with a trivalent vaccine in modified vaccinia virus Ankara. J. Virol. 70:1996;3741-3752.
10. Hanke T., Samuel R., Blanchard T.J., Neumann V.C., Allen T.M., Boyson J.E., et al. Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multi-epitope DNA prime-modified vaccinia virus Ankara boost vaccination regimen. J. Virol. 73:1999;7524-7532.
11. Chakrabarti S., Brechling K., Moss B. Vaccinia virus expression vector: co-expression of β-galactosidase provides visual screening of recombinant virus plaques. Molec. Cell. Biol. 5:1985;3403-3409.
12. Parker C.E., Gould K.G. Influenza A virus - a model for viral antigen presentation to cytotoxic T lymphocytes. Semin. Virol. 7:1996;61-73.
13. Dorrell L., Dong T., Ogg G.S., Lister S., McAdam S., Rostron T., et al. Distinct recognition of non-clade B human immunodeficiency virus type 1 epitopes by cytotoxic T lymphocytes generated from donors infected in Africa. J. Virol. 73:1999;1708-1714.
14. Krausa P., Bodmer J.G., Browning M.G. Defining the common subtypes of HLA-A9, A10, A28 and A19 by use of ARMS-PCR. Tiss. Antigens. 42:1993;91-99.
15. McAdam S., Kaleebu P., Krausa P., Goulder P.J.R., French N., Collin B., et al. Cross-clade recognition of p55 by CTL in HIV-1 infection. AIDS. 12:1998;571-579.
16. Lalvani A., Dong T., Ogg G., Patham A.A., Newell H., Hill A.V., et al. Optimisation of a peptide-based protocol employing IL-7 for in vitro restimulation of human cytotoxic T lymphocyte precursors. J. Immunol. Meth. 210:1997;65-77.
17. Gotch F.M., Rothbard J., Howland K., Townsend A., McMichael A.J. Cytotoxic T lymphocytes recognise a fragment of influenza matrix protein in association with HLA-A2. Nature. 326:1987;881-882.
18. Nixon D.F., Townsend A.R.M., Elvin J.G., Rizza C.R., Gallwey J., McMichael A.J. HIV-1 gag-specific cytotoxic T lymphocytes defined with recombinant vaccinia virus and synthetic peptides. Nature. 336:1988;484-487.
19. Lalvani A., Brookes R., Hambleton S., Britton W.J., Hill A.V.S., McMichael A.J. Rapid effector function in CD8+ memory T cells. J. Exp. Med. 186:1997;859-865.
20. Altman J.D., Moss P.A.H., Goulder P.J.R., Barouch C.H., McHeyzer-Williams M.B., Bell J.I., et al. Phenotypic analysis of antigen-specific T lymphocytes. Science. 274:1996;94-96.
21. Morris A.G., Lin Y.-L., Askonas B. Immune interferon release when a cloned cytotoxic T cell line meets its correct influenza-infected target cell. Nature. 259:1982;150-152.
22. Yewdell J.W., Bennink J.R., Smith G.L., Moss B. Influenza virus A nucleoprotein is a major target for cross-reactive anti-influenza virus cytotoxic T lymphocytes. Proc. Nat. Acad. Sci. USA. 82:1985;1785-1789.
23. Rowland-Jones S., Sutton J., Ariyoshi K., Dong T., Gotch F., McAdam S., et al. HIV-specific cytotoxic T lymphocytes in HIV-exposed but uninfected Gambian women. Nat. Med. 1:1995;59-64.
24. Aidoo M., Lalvani A., Whittle H., Hill A.V.S., Robson K.J. Recombinant vaccinia viruses for the characterisation of Plasmodium falciparum-specific cytotoxic T lymphocytes: recognition of processed antigen despite limited restimulation efficacy. Int. Immunol. 9:1997;731-737.
25. Matsuo H., Batocchi A.-P., Hawke S., Nicolle M., Jacobson Z., Vincent A., et al. Peptide-selected T cell lines from myasthenia gravis patients and controls recognise epitopes that are not processed from the whole acetyl choline receptor. J. Immunol. 155:1995;3683.
26. Larsson M., Jin X., Ramratnam B., Ogg G.S., Engelmayer J., Demoitie M.A., et al. A recombinant vaccinia virus based ELISPOT assay detects high frequencies of Pol-specific CD8 T cells in HIV-1-positive individuals. AIDS. 13:1999;767-777.
27. Ennis A.F., Meager A. Immune interferon produced to high levels by antigenic stimulation of human lymphocytes with influenza virus. J. Exp. Med. 154:1981;1279-1289.
28. Balkwell F.R. Interferons. Lancet. 8646:1989;1060-1063.
29. di Fabio S., Mbawulke I.N., Kiyono H., Fujihashi K., Couch R.B., McGhee J.R. Quantitation of human influenza virus-specific cytotoxic T lymphocytes: correlation of cytotoxicity and increased numbers of IFN-γ producing CD8+ T cells. Int. Immunol. 6:1994;11-19.
30. Kuroda M.J., Schmitz J.E., Barouch D.H., Craiu A., Allen T.M., Sette A. Analysis of gag-specific cytotoxic T lymphocytes in simian immunodeficiency virus-infected rhesus monkeys by cell staining with a tetrameric major histocompatibility complex class I-peptide complex. J. Exp. Med. 187:1998;1373-1381.
31. Gallimore A., Glithero A., Godkin A., Tissot A.C., Pluckthun A., Elliot T., et al. Induction and exhaustion of lymphocytic choriomeningitis virus-specific cytotoxic T lymphocytes visualised using soluble tetrameric major histocompatibility complex class I-peptide complexes. J. Exp. Med. 187:1998;1383-1393.